Quince Therapeutics, Inc. (QNCX) › Operating IncomeQuince Therapeutics, Inc. (QNCX) — Operating IncomeAnnual figures by fiscal year, from SEC filings.2018: -$12.12M2019: -$39.17M2020: -$78.89M2021: -$90.32M2022: -$52.02M2023: -$34.62M2024: -$57.28M2025: -$58.07M-$58.07M2018Operating Income (USD)2025Fiscal YearOperating IncomeChange YoY2025-$58.07M-1.4%2024-$57.28M-65.5%2023-$34.62M+33.4%2022-$52.02M+42.4%2021-$90.32M-14.5%2020-$78.89M-101.4%2019-$39.17M-223.2%2018-$12.12M—Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share